spike protein and is adjuvanted with Matrix-M as the active substance and it and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
nuvaxovid-epar-risk-management-plan-summary_en.pdf
26 jan 2021 · The glycoforms present on SARS-CoV-2 S-I53-50NPs are more processed compared to other recombinant S protein immunogens (Watanabe et al , 2020)
S0092-8674(21)00078-7.pdf
16 déc 2021 · Phase I/II • Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine Keech C, Albert G, Cho I, et al
nvx-evidence-assessment-sage-17-dec-2021.pdf
20 déc 2021 · NVX-CoV2373 is a recombinant spike protein nanoparticle-based vaccine It contains the full-length SARS-CoV-2 spike protein
WHO-2019-nCoV-vaccines-SAGE-recommendation-Novavax-NVX-CoV2373-background-2021.1-eng.pdf
19 nov 2021 · live attenuated vaccines, and recombinant protein vaccines) and DNA Structure of the SARS-CoV-2 spike (S) protein S protein exists as
PIIS2352-3964(21)00493-X.pdf
6 août 2020 · is a recombinant nanoparticle vaccine constructed from the full-length, wild-type SARS-CoV-2 spike glycoprotein, which mediates viral attachment
keech_medRxiv2020_NVXFirst-in-HumanTrialofaSARS-CoV-2RecombinantSpikeProteinNanoparticleVaccine.pdf